Pune, July 08, 2019 (GLOBE NEWSWIRE) -- The global Hereditary Angioedema Treatment Market to gain from increasing incidences of genetic mutation. Recently Fortune Business Insights, published a report titled, “Hereditary Angioedema Treatment Market Size, Share and Global Trend by Drug Class (C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), Application (Prophylaxis, Treatment), Route of Administration (IV, Subcutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2025.” As per the report, the global Hereditary Angioedema Treatment Market was worth US$ 1883.1 Mn in 2017. The global market is anticipated to expand at a CAGR of 16.8% and reach US$ 6533.3 Mn by the end of 2025. The report classifies the global Hereditary Angioedema Treatment Market in various segments and offer a comprehensive overview.
According to the report, the Hereditary Angioedema Treatment Market in North America was valued at US$ 1752.2 Mn in 2017. The growth witnessed is attributable to high prevalence of hereditary angioedema in the region. North America may remain dominant in the global market through the forecast period (2018-2025).
Browse Complete Report Details with Table of Content and Figures:
https://www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164
Presence of an established healthcare system and increasing healthcare expenditure are a few factors anticipated to contribute the expansion of the Hereditary Angioedema Treatment Market in North America. The report also predicts the market in Asia Pacific to witness impressive growth. Increasing medical tourism in nations such as China and India will create lucrative growth opportunities for the market in the region. Besides this, increasing number of product innovations in the region backed by high presence of hereditary angioedema drugs manufacturers will give tailwinds to growth witnessed by the Hereditary Angioedema Treatment Market.
C-1 Esterase Inhibitor Segment to Dominate Global Market During Forecast Period
In terms of drug class, the C-1 esterase inhibitor is the most popular drug and dominated the global Hereditary Angioedema Treatment Market in 2017. The segment accounted for 61.3% of the global market in 2017. The trend is unlikely to change during the forecast period 2018-2025 owing to the drug’s reliability among patients and practitioners.
Increasing awareness about the disorder and rising prevalence of the hereditary angioedema are some factors expected to drive the global Hereditary Angioedema Treatment Market during the forecast period. Additionally, technological developments in the hereditary angioedema treatment devices and equipment is expected to boost the global market.
According to the U.S. Hereditary Angioedema Association, hereditary angioedema may not necessarily occur due to prior familial history of the disease. In 25% of the cases hereditary angioedema may arise due to spontaneous mutation of the gene called C-1 inhibitor. This is anticipated to enable growth in the global Hereditary Angioedema Treatment Market.
On the flip side, the side effects and high cost associated with hereditary angioedema drugs and treatment is the major factor that may restrain the global Hereditary Angioedema Treatment Market.
Shire, CSL Behring, and Pharming Group NV to Lead the Global Market
The global Hereditary Angioedema Treatment Market is witnessing entry of new players in the market. However, at present Pharming Group NV, Shire, and CSL Behring are together leading the global market owing to the organization’s strong distribution network.
The report provides elaborative analysis of the market dynamics and competitive landscape. Various key insights provided in the report are key strategies of leading market players, epidemiology of hereditary angioedema – for key countries, pipeline analysis, and introduction of new products/approvals (by major players).
Key Companies Covered in The Report
- CSL Behring
- Shire plc.
- Pharming Group NV
- BIOCRYST PHARMACEUTICALS, INC.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum
- Other prominent players
Speak to Analyst https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/hereditary-angioedema-treatment-market-100164
Table of Content:
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Key Strategies of Leading Market Players
- Epidemiology of Hereditary Angioedema – for Key Countries
- Pipeline Analysis
- Introduction of New Products/Approvals (by Major Players)
- Global Hereditary Angioedema Treatment Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Drug Class
- C-1 Esterase Inhibitors
- Bradykynin Receptor Antagonist
- Kallikrein Inhibitors
- Market Analysis, Insights and Forecast – By Application
- Prophylaxis
- Treatment
- Market Analysis, Insights and Forecast – By Route of Administration
- IV
- Subcutaneous
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Rest of the World
- Competitive Analysis
- Strategic Recommendations
Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/hereditary-angioedema-treatment-market-100164
Browse Related Reports:
- Neurodegenerative Diseases Drugs Market Size, Share and Global Trend By Drug Class (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists), By Disease Indication (Multiple Sclerosis, Parkinson’s Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA)), By Route of Administration(Oral, Injection, Transdermal) By End User(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026
- Intravenous Immunoglobulins Market Size, Share and Global Trend By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), Form (Liquid, Lyophilized), End User (Hospitals, Clinics, Homecare) & Geography Forecast till 2025
- Immunoglobulins Market Size, Share and Global Trend By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form(Liqui, Lyophilized), By End User(Hospitals, Clinics, Homecare) and Geography Forecast till 2026
- Rheumatoid Arthritis Therapeutics Market Size, Share and Global Trend By Product Type (Biologics, Non-Biologics), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) & Geography Forecast till 2025
About us:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact us:
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
US :+1-424-253-0390
UK :+44-2071-939123
APAC :+91-744-740-1245
Email: sales@fortunebusinessinsights.com
Website: https://www.fortunebusinessinsights.com
Attachment